Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
暂无分享,去创建一个
M. Beksac | I. Yakoub-Agha | J. Passweg | S. Schönland | J. Sanz | J. Finke | L. Rosiñol | M. Minnema | T. Zuckerman | P. Lenain | C. Koenecke | M. Hänel | L. D. de Wreede | L. Gras | P. Hayden | S. Ducastelle | W. Schroyens | L. Koster | S. Harel | L. Vincent | F. Monaco | P. Céballos | R. Teipel | J. V. van Doesum | C. Botella-Garcia | M. Beksaç